z-logo
open-access-imgOpen Access
Equol, Adiponectin, Insulin Levels and Risk of Breast Cancer
Author(s) -
Machiko Minatoya,
Goro Kutomi,
Sumiyo Asakura,
Seiko Otokozawa,
Yukiko Sugiyama,
Yoshie Nagata,
Mitsuru Mori,
Koichi Hirata
Publication year - 2013
Publication title -
asian pacific journal of cancer prevention
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.512
H-Index - 75
eISSN - 2476-762X
pISSN - 1513-7368
DOI - 10.7314/apjcp.2013.14.4.2191
Subject(s) - adiponectin , breast cancer , medicine , obesity , insulin , equol , oncology , isoflavones , cancer , endocrinology , insulin resistance , daidzein , genistein
Breast cancer is one of the most frequently diagnosed cancers and the leading cause of cancer death among women. Soy isoflavones have been widely studied and among all isoflavones equol has been gaining interest with regard to its relationship with breast cancer risk. Obesity has been revealed as one of the breast cancer risk factors, known to be associated with high levels of circulating insulin and decreased levels of adiponectin. Hence there have been many studies investigating relationships between insulin and adiponectin levels and breast cancer risk. Additionally recent findings have suggested that insulin and adiponectin themselves may have influence on breast cancer development, independent of obesity. In the present review, we discuss the relationships between breast cancer risk and equol, insulin and adiponectin levels, which are three important factors in our ongoing hospital-based case-control study. Herein these factors are reviewed not only from the clinical viewpoint but also from possible chemical and biological points of view which may explain clinical observations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom